November 3, 1993, abandoned. The application also claims priority to PCT/US 94/08423, filed on July 26, 1994. The application also claims priority to USSN 08/280,757, filed on July 26, 1994, pending; which is a continuation-in-part of USSN 08/109,393, filed August 19, 1993, pending; which is a continuation-in-part of USSN 08/101,624, filed on July 26, 1993, abandoned. The contents of these applications are specifically incorporated herein by reference.--

In the Claims:

Please cancel claims 1-41 and 44-45 without prejudice.

Please amend the claims as follows:

46. (Amended) A method of treating a subject with a tumor, comprising:

(a) obtaining tumor cells from the subject;

(b) transfecting the tumor cells with a nucleic acid encoding B7-2 in a form suitable for expression of B7-2 such that B7-2 is expressed by the tumor cell; and

(c) administering the tumor cells to the subject.

Please add the following new claims:

--65. The method of claim 46, wherein B7-2 comprises the amino acid sequence shown in SEQ ID NO:2.

66. The method of claim 46, wherein the nucleic acid encoding B7-2 molecule the nucleic sequence shown in SEQ ID NO:1.

67. The method of claim 58, wherein B7-2 molecule the amino acid sequence shown in SEQ ID NO:2.

68. The method of claim 58, wherein the nucleic acid encoding B7-2 comprises the nucleic sequence shown in SEQ ID NO:1.

69. The method of claim 60, wherein B7-2 comprises the amino acid sequence shown in SEQ ID NO:2.

70. The method of claim 60, wherein the nucleic acid encoding a B7-2 molecule comprises the nucleic sequence shown in SEQ ID NO:1.

71. The method of claim 62, wherein B7-2 comprises the amino acid sequence shown in SEQ ID NO:2.

72. The method of claim 62, wherein the nucleic acid encoding B7-2 comprises the nucleic sequence shown in SEQ ID NO:1.

73. A method of modifying a tumor cell to express a B7-2 molecule comprising, transfecting a tumor cell with a nucleic acid molecule encoding a B7-2 molecule such that B7-2 is expressed by the tumor cell.

74. The method of claim 73 wherein tumor cell is modified by transfection with a nucleic acid molecule comprising the nucleotide sequence shown in SEQ ID NO:1.

75. The method of claim 73, wherein the tumor cell is modified *in vitro* or *ex vivo.*

76. The method of claim 73, wherein the tumor cell is modified *in vivo.*

77. The method of claim 73, wherein the tumor cell is further transfected with at least one nucleic acid molecule encoding a B7 protein.

78. The method of claim 73 wherein the tumor cells are further transfected with at least one nucleic acid molecule encoding at least one MHC class II αchain protein and at least one MHC class II β chain protein in a form suitable for expression of the MHC class II αchain protein(s) and the MHC class II β chain protein(s).

79. The method of claim 73 wherein the tumor cells are further transfected with at least one nucleic acid molecule encoding at least one MHC class I α chain protein in a form suitable for expression of the MHC class I protein(s).

80. The method of claim 73 wherein the tumor cells are further transfected with a nucleic acid molecule encoding a β-2 microglobulin protein in a form suitable for expression of the β-2 microglobulin protein.

81. The method of claim 73 wherein expression of an MHC class II associated protein, the invariant chain, is inhibited in the tumor cells.

82. The method of claim 81 wherein expression of the invariant chain is inhibited in the tumor cells by transfection of the tumor cell with a nucleic acid which is antisense to a regulatory or a coding region of the invariant chain gene.

83. The method of claim 73 wherein the tumor is a sarcoma.

84. The method of claim 73 wherein the tumor is a lymphoma.

85. The method of claim 73 wherein the tumor is selected from a group consisting of a melanoma, a neuroblastoma, a leukemia and a carcinoma.

86. The method of claim 73, wherein the B7-2 molecule comprises the amino acid sequence shown in SEQ ID NO:2.

87. A method of increasing the immunogenecity of a tumor cell comprising, modifying the tumor cell to express a B7-2 T cell costimulatory molecule such that the immunogenecity of the tumor cell is increased.--

REMARKS

Claims 1-64 were present in parent application 08/456,104 as filed. Claims 1-41, 44 and 45 have been canceled. Claims 65-87 have been added. Accordingly, claims 42, 43, and 46-87 are currently pending in the application. For the Examiner's convenience, a copy of the claims as currently pending is provided in Appendix A.

Support for the above claim amendments can be found through out the specification and claims as originally filed. Support for the inclusion SEQ ID NO:s 1 and